Scholarlink

Our case was an elderly woman with small cell lung cancer who presented with grade 3 diarrhea and grade 2 colitis after 1 year of immune checkpoint inhibition with atezolizumab that was refractory to treatment with steroids and infliximab. Her symptoms improved after administration of vedolizumab and ustekinumab, but she was unable to take these medications due to a severe allergic reaction (sinusitis and arthralgias). Her condition stabilized after fecal microbiota transplant which enabled her to resume atezolizumab long term with favorable cancer outcome, however, had recurrent colitis symptom after 1 year, which benefited from repeat fecal transplant treatment.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Colitis Following Immune Checkpoint Inhibitor Therapy

  • 章节

  • 发表日期：

    2025年

查看全文
  • Malek Shatila,
  • Krishnavathana Varatharajalu,
  • Herbert Dupont,
  • Robert Jenq,
  • Franck Carbonnel,
  • Stephen Hanauer,
  • Anusha S. Thomas,
  • Yinghong Wang

摘要

Our case was an elderly woman with small cell lung cancer who presented with grade 3 diarrhea and grade 2 colitis after 1 year of immune checkpoint inhibition with atezolizumab that was refractory to treatment with steroids and infliximab. Her symptoms improved after administration of vedolizumab and ustekinumab, but she was unable to take these medications due to a severe allergic reaction (sinusitis and arthralgias). Her condition stabilized after fecal microbiota transplant which enabled her to resume atezolizumab long term with favorable cancer outcome, however, had recurrent colitis symptom after 1 year, which benefited from repeat fecal transplant treatment.